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Introduction
Schizophrenia and bipolar disorder are a set of complex, polygenic illnesses that cause
enormous human suffering. Little is known about their molecular etiology, although their
high heritability suggests that genome sequence variation must contain important clues.
Early strategies to identify the genetic contributions to complex diseases included linkage
analysis and candidate gene association studies, but were limited by sample size and (in
retrospect) an insufficient appreciation of the complexity of these disorders. We now
understand that these disorders are influenced by many genetic and environmental factors,
few if any of which are deterministic, and almost all of which have required large, well-
powered studies to discover and replicate.
The Center for Genomic Psychiatry at the University of Southern California (USC) and an
extensive network of academic medical centers have created the Genomic Psychiatry
Cohort (GPC) (n=33,000). We have ascertained and enrolled a large clinical cohort of
patients with schizophrenia (n=10,000), patients with bipolar disorder (n=5,000), family
members (n=3,000), and control participants with no personal or family history of
schizophrenia or bipolar disorder (n=15,000). The GPC was formed from an initial
population of ~10,000 participants from our earlier studies. Over the past four years, we
have enrolled an additional 23,000 participants (~9,000 Caucasian, ~5,000 African
American, ~8,000 Latino, ~1,000 other).
The initial 10,000 GPC participants drawn from earlier studies include our Portuguese
Island Collection (PIC) of individuals and multiplex families with schizophrenia and/or
bipolar disorder. The PIC sampled a homogeneous population founded 500 years ago on two
island archipelagos off the coast of Portugal (Pato et al, 2004; Sklar et al, 2004). The PIC
has been an integral part of the International Schizophrenia Consortium (ISC). We
reported, as part of the ISC, on the presence of copy number variants (CNVs) in our
population that significantly increased risk at 22q11.2, 15q13.2, and 1q21.1 (ISC, 2008). We
also demonstrated that risk for schizophrenia is significantly affected by common polygenic
variation and that those risks may also contribute to the risk for bipolar disorder (ISC, 2009).
These findings were rapidly replicated in other studies (Stefansson et al., 2008; Stefansson et
al., 2009; Shi et al., 2009). Our group has continued to extend these findings in a number of
follow-up publications (Ng et al., 2009; O’Dushlaine et al., 2011; Gilks et al, 2010;
Moskvina et al., 2010; Chen et al., 2011; Raychaudhuri et al., 2010; Pato et al., 2010;
Bridges et al., 2011; Chen et al., 2011; Sullivan et al., 2012; Jia et al., 2012a,b; Fanous et al.,
2012a,b; Keller et al., 2012; Derks et al., 2012; Richards et al., 2012; Bigdeli et al., 2013).
We collaborated with the other members of the Psychiatric Genomic Consortium (PGC)
to include all available populations in a genome-wide association study (GWAS) of
schizophrenia. The PGC reported five new schizophrenia loci in 2011 (Ripke et al., 2011).
An expanded analysis of more than 30,000 patients and 35,000 controls is ongoing and
appears highly successful (Ripke and Ruderfer, 2012).
Replication and extension of findings will require even larger sample sizes. With the
development of the GPC, we hope to continue consortium efforts and to develop new
collaborations that will lead to discoveries not only in genetic etiology but also in disease
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definition, endophenotypic measures, co-morbidities, treatment, and other clinical and
epidemiological areas.
GPC Characteristics
In order to assure ongoing careful assessment of phenotype and the possibility of future
studies, GPC members are informed that they may be re-contacted and are given the
opportunity to opt out. We are able to re-contact more than 88% of the participants. The re-
contactable cohort is available for ongoing and new studies; the population characteristics
are presented in Table 1. The GPC resource includes an NIMH-managed repository of
genomic samples, genome-wide SNP and whole genome sequence data, and detailed clinical
and demographic data for investigations of schizophrenia and bipolar disorder.
Participant Ascertainment and Confidentiality
The Center for Genomic Psychiatry at USC is the lead site and coordinating center for
twelve clinical collaborators in the United States and abroad. A novel performance-based
system for awarding site subcontracts allowed flexibility to increase or decrease funding
based on achievement of enrollment milestones. Study instruments and procedures were
developed to enable computer-assisted targeted interviews focused on psychotic and
affective symptoms and to allow algorithm-based diagnoses to be achieved.
Participants are recruited from urban, suburban, and rural populations across the United
States and in selected sites abroad. Individuals suffering from schizophrenia or bipolar
disorder are ascertained as in-patients in acute care or chronic care settings, as out-patients,
or as residents in community dwellings. Control participants are drawn from the same
geographic area as case participants, either within health care facilities or as community
volunteers.
To best ensure participant privacy and confidentiality, all personal identifiers are maintained
at the local collaborating site and re-contact of consenting participants is through that site.
Informed consent templates were developed at USC following NIMH guidelines and
adapted as necessary for site-specific institutional review board (IRB) approval. A
Certificate of Confidentiality from the Department of Health and Human Services also was
obtained. With these protections in place, data on individual participant demographics,
phenotypes and genotypes as well as biological samples are transmitted to public
repositories and databases in accordance with our Distribution Agreement with the NIMH
Center for Collaborative Genetic Studies. All research involving human subjects is in
compliance with the Code of Ethics of the World Medical Association (Declaration of
Helsinki) and, as noted, with the standards established by each author's IRB and the funding
agency, NIMH.
Screening Questionnaire
Both potential cases (patients suffering with schizophrenia and bipolar disorder) and
controls (unaffected participants) were asked to complete a questionnaire (Supplementary
Information: Screening Questionnaire) to assess their psychiatric history and the psychiatric
history of all first-degree relatives. Individuals reporting any lifetime symptoms indicative
of psychosis or mania were excluded as control participants.
The Screening Questionnaire is a compilation of questions from well-validated interviews
and includes 32 questions and screens for mania, psychosis, depression, anxiety disorder,
alcohol, nicotine and other substance use history. In addition, there is a section on
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demographic information (i.e., age, gender and self-identifying race and ethnicity) and a
section on medical conditions and disorders including head trauma and seizure history.
Diagnosis
All participants enrolled as probable cases were interviewed using the Diagnostic Interview
for Psychosis and Affective Disorders (DI-PAD) (Supplementary Information: DI-PAD).
We developed the DI-PAD specifically for the GPC study using the same principles as were
applied in the development of the Diagnostic Interview for Psychosis – Diagnostic Module
(DIP-DM) (Castle et al., 2006). The DI-PAD is a semi-structured clinical interview that
includes two modules: Diagnostic Module and Substance Abuse Module. The DI-PAD is
administered by mental health professionals and requires more than a simple notation of
presence or absence of a symptom. Specific training is necessary to ensure reliability of
ratings. At this time, the DI-PAD is available in English, Portuguese, and Spanish.
The DI-PAD uses questions developed for the Diagnostic Interview for Genetic Studies
(DIGS) (Nurnberger et al., 1994). This optimizes comparability with the many studies,
including our PIC studies that used the more extensive DIGS questionnaire. The DI-PAD
then links to the Operational Criteria Checklist for Psychotic Illness (OPCRIT). The
OPCRIT is a 90-item checklist and computerized diagnostic algorithm (McGuffin et al.,
1991; Williams et al., 1996), and has been successfully used in the genetic analysis of
phenotypic heterogeneity in both schizophrenia (Fanous et al., 2005) and bipolar disorder
(Schulze et al., 2005). OPCRIT diagnoses can be based on a variety of different systems. All
GPC OPCRIT diagnoses are based on DSM-IV-TR criteria (American Psychiatric
Association, 2000). The DI-PAD modules provide an efficient and consistent method to
collect the required data both from patient and informant interviews and through record
review. In earlier studies, we found excellent agreement (kappa = 0.8) between interviewer
OPCRIT diagnoses, such as those derived from the DI-PAD, and the best-estimate lifetime
consensus procedure (Azevedo et al., 1999). A team of clinicians reviewed all diagnoses. In
nearly one quarter of cases, our best estimate diagnosis process supplemented OPCRIT-
based diagnoses.
DI-PAD Training
All interviewers receive structured training on the use of the DI-PAD. The DI-PAD training
is done in person by master raters. A critical element is side-by-side interviews with
psychiatric patients by both the trainer and the trainee. Ongoing support is provided to all
sites. The lead trainer visits each site yearly. During the site visits, the trainer observes in-
vivo interviews and rates alongside the interviewer. Additionally, inter-rater and inter-site
reliability tests are conducted yearly.
GPC Network
GPC participants were primarily recruited from populations in eight US states: California
sites at the University of Southern California, University of California at Los Angeles,
Cedars Sinai Medical Center, and University of California at Irvine; Georgia sites at Emory
University and Georgia Regents University; Massachusetts sites at various Department of
Mental Health and community clinics; New York sites at New York University, State
University of New York at Stony Brook, and State University of New York, Upstate
Medical University Syracuse; North Carolina site at University of North Carolina at Chapel
Hill; Texas sites at Texas Tech University in El Paso and San Antonio; and Ohio site at
Wright State University. Each GPC study site team consists of a site coordinator, field
interviewers, and certified phlebotomists.
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We made a strategic decision to focus on achieving our targeted cohort size of >30,000 GPC
participants. We chose to concentrate our case ascertainment and participant enrollment on
individuals with clear clinical diagnoses. Potential cases were drawn from patients whose
diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder had been consistent
from their treating psychiatrist and in their medical records. Using these initial screening
procedures, less than one percent of individuals initially recruited as potential cases failed to
meet criteria for one of the diagnoses under study after DI-PAD interview and OPRIT/best
estimate diagnoses. A great deal of effort in many prior studies was focused on the least
clear cases; such cases often remained unclear even after extremely thorough best estimate
processes.
Each site began with patients being treated in their own health care delivery systems,
including out-patient clinics and hospitals. As recruitment efforts broadened, case
participants were also drawn from residential facilities (board and care), and from outpatient
community mental health clinics. After initial telephone contact in which the research
protocol was described, study informational material and flyers were mailed to potential
recruitment sites for review by clinicians, staff, and potential participants. Research
coordinators traveled to these facilities to meet with clinicians/case-management teams to
describe the study in detail and to address questions. We have established a broad network
of participating sites that enable ongoing contact with cohort participants.
Geographically matched control participants were recruited from general medical offices,
community health fairs, churches, public health events, and through advertisements in local
newspapers and Craigslist and posts on social media sites (e.g., Facebook; Twitter). Only
one person per family (first and second degree relatives) was eligible to participate.
In addition to the completion of the Screening Questionnaire and, for likely cases, the DI-
PAD, all participants donated up to 50 milliliters of blood. Samples were express mailed
directly to the NIMH Repository at Rutgers University (Rutgers University Cell and DNA
Repository, RUCDR). Many collaborators also retained additional samples.
Prospective Follow-up and Re-contact
Both participants suffering from schizophrenia and bipolar disorder and controls were asked
to actively participate in the GPC. In addition to completing study instruments and donating
blood, all participants were asked for consent to release of medical records. Most GPC
participants have given long-term prospective access to their medical records (>20 years).
As the electronic health record (EHR) becomes more widely used, we are implementing a
parallel research record that, with permission, regularly queries the GPC participant’s
electronic health records to maintain close prospective follow-up of health and treatment
course. Further, to optimize our ability to prospectively follow our GPC participants, 88%
can be re-contacted and invited to participate in further studies.
The coordinating center at USC uses an electronic health record (Cerner Corporation,
Kansas City, MO) a comprehensive implementation of a continuum of care record spanning
inpatient, outpatient, procedural, and behavioral health care. As part of USC’s overall
commitment to research, the institution is developing a parallel research oriented clinical
data warehouse. Appropriate data governance allows for those patients who have given
consent (such as in the GPC cohort) to have their records queried and then re-queried when
updated. For our GPC cohort, this process will allow continuous expansion of the
phenotypic data set. The majority of GPC participants reside in the Los Angeles region. The
USC system and the Los Angeles County Department of Health Services are actively
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exploring the unique opportunity to amalgamate the research data warehouses across both
organizations. The successful implementation of this will greatly enhance our ability to
prospectively follow up our Los Angeles based participants. Parallel strategies are being
developed with our collaborating sites for access to their local GPC participant’s EHR.
Collaborative Investigator Network
The GPC has created a system that allows outside investigators, with appropriate review and
approval, to collaborate in, propose, and co-lead studies involving GPC participants. Our
goal in establishing the GPC has been to establish a resource for the field. To this end, we
have sought to collaborate with experts in various fields, leading to several new
collaborative research projects (Table II). We have established a GPC Protocol Review
Committee with selected site principal investigators (PIs), selected collaborating PIs, and an
NIMH representative that reviews and recommends approval of projects involving GPC
participants that are proposed by outside investigators.
The majority of the participants in the GPC have approved data sharing through dbGaP.
Some participants were ascertained and included before the creation of dbGaP, but data are
available through the NIMH or through the GPC directly. The NIMH Human Genetics
Initiative has an established process to enable and approve the use of samples and data from
the GPC. Investigators may apply as usual to the NIMH Human Genetics Initiative. We
recommend that investigators include the GPC Protocol Review Committee as they apply to
NIMH. This allows us to encourage joint efforts when different investigators make the same
or related proposals and better achieve scale. If participant re-contact or other type of
collaborative study is planned, investigators should apply to the GPC Protocol Review
Committee. This will ensure creation of a large coordinated database of genetic and
phenotypic data contributed by a wide array of investigators each with particular specialties
(e.g., substance abuse, neuroimmunology, functional imaging).
The goal is to assure access for high quality and high impact projects that show promise to
advance the field, while also managing the involvement of GPC participants to assure that
privacy and confidentiality are maintained. The sharing of data between projects and with
the field through the NIMH Human Genetics Initiative is an expectation for all GPC
projects, and we expect that the results from all projects will be available to inform the
analyses in any other collaborative project.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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